[Form 4] Ultra Clean Holdings, Inc. Insider Trading Activity
Ultra Clean Holdings, Inc. (UCTT) officer Jinsong Xiao received a grant of 117,948 restricted stock units on 09/26/2025. The award is reported as acquisition of common stock units at a reported price of $0, and the securities are held directly following the transaction. The restricted stock units vest in three equal annual installments beginning on the vesting commencement date of 09/26/2025, meaning one-third vests each anniversary over three years. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on behalf of Mr. Xiao.
- Alignment with shareholders: CEO receives time‑based RSUs that vest over three years, which can align management incentives with long‑term performance
- Transparent insider disclosure: Transaction date, number of units, vesting commencement date, and vesting schedule are explicitly reported
- None.
Insights
TL;DR: CEO received time-based RSUs aligning incentives with long-term shareholder value; disclosure is routine.
The Form 4 documents a time-based equity grant to the company's CEO totaling 117,948 restricted stock units that vest over three years. Such awards are a common executive compensation mechanism to retain leadership and align management incentives with long-term performance. The direct ownership form and zero reported price indicate these are compensation units rather than open-market purchases. From a governance standpoint, the grant is material to insider alignment but routine in nature; no additional compensation terms, acceleration provisions, or cash value are disclosed in this filing.
TL;DR: Vesting schedule is straightforward; lacking value disclosure limits assessment of grant magnitude.
The award's structure—three equal annual vesting tranches starting 09/26/2025—is clear and supports retention over a multi-year horizon. However, the Form 4 does not state the grant's fair value, total dilution impact, or any performance conditions, restricting quantitative assessment of its compensation significance. Without grant-date valuation or company disclosure of total shares outstanding here, the investor impact cannot be precisely measured from this filing alone.